Charles Schwab’s 9 Meters Biopharma NMTR Stock Holding History

Charles Schwab’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,388	Closed	-$24K	–	3581
2022 Q3	$24K	Hold	5,388	–	–	﹤0.01%	3465
2022 Q2	$29K	Sell	5,388 -25,491	-83%	-$240K	﹤0.01%	3486
2022 Q1	$371K	Hold	30,879	–	–	﹤0.01%	3166
2021 Q4	$605K	Buy	30,879 +1,722	+6%	+$38.5K	﹤0.01%	3090
2021 Q3	$759K	Buy	29,157 +3,226	+12%	+$76K	﹤0.01%	2985
2021 Q2	$571K	Buy	25,931 +22,529	+662%	+$553K	﹤0.01%	3123
2021 Q1	$80K	Buy	+3,402	New	+$105K	﹤0.01%	3398
2019 Q2	–	Sell	-1,725	Closed	-$67K	–	3281
2019 Q1	$67K	Hold	1,725	–	–	﹤0.01%	3104
2018 Q4	$80K	Hold	1,725	–	–	﹤0.01%	3107
2018 Q3	$236K	Hold	1,725	–	–	﹤0.01%	3050
2018 Q2	$814K	Buy	+1,725	New	+$635K	﹤0.01%	2646

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Charles Schwab's NMTR Position: Q4 2022 in Review

Charles Schwab sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 5,388 shares — an estimated $24K sold.

Charles Schwab first reported a position in NMTR in Q2 2018 and held it in 11 quarters. The position peaked at $814K in Q2 2018. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Charles Schwab reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Charles Schwab sold 5,388 9 Meters Biopharma shares in Q4 2022, an estimated $24K.
Charles Schwab first reported a position in 9 Meters Biopharma in Q2 2018 and held it in 11 quarters.
Charles Schwab's 9 Meters Biopharma position peaked at $814K in Q2 2018.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.